Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB ...
The STOPMD-3 trial investigated the effects of oral SPI-1005 in 201 Meniere’s disease patients to restore sensory neural hearing loss. In July 2024, Sensorion SA announced that the company has ...